Methods of Identifying and Treating Tumors that Express Erythropoietin Receptor Protein (EPOR)
Description of Invention:
The inventors have discovered that EPO and EPOR are co-expressed in tumors of von Hippel-Lindau (VHL) patients and in tumors of sporadic renal tumor patients. Ligands that bind to EPOR but do not activate the receptor can target specific tumor cells with minimal detrimental effect on normal cells.
Applications:
Treatment and diagnosis of renal tumors in sporadic and kidney dialysis patients
Treatment and diagnosis of multiple tumors in different organs in patients with von Hippel-Landau patients
Treatment and diagnosis of pheochromocytomas
Treatment and diagnosis of eye and CNS hemangioblastomas
Inventors:
Zhengping Zhuang et al. (NINDS)
Patent Status:
DHHS Reference No. E-274-2004/0 Licensing Status: This technology is no longer available for licensing.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro Cancer -Diagnostics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
